Bone metabolic indices: Promising predictors for assessing acromegaly

Area of Science:

• Endocrinology
• Bone Metabolism
• Acromegaly Research

Background:

• Acromegaly, a chronic endocrine disorder, frequently presents with joint and bone complications.
• The precise relationship between bone metabolism and acromegaly pathogenesis remains incompletely understood.
• Understanding these links is crucial for managing acromegaly patients and their skeletal health.

Purpose of the Study:

• To investigate the correlation between bone metabolism indices and acromegaly severity.
• To evaluate the predictive value of bone metabolism markers in acromegaly patients.
• To assess changes in bone metabolism markers post-acromegaly treatment.

Main Methods:

• Inclusion of 31 acromegaly patients from Peking Union Medical College Hospital.
• Measurement of bone metabolism indices (β-CTX, TP1NP, T-25OHD, 1,25(OH)2D3) and acromegaly severity (SAGIT score) pre-operation.
• Follow-up for at least 3 months post-operation to assess treatment outcomes and marker changes.

Main Results:

• Significant reductions in β-CTX and TP1NP observed in the acromegaly remission group post-surgery (p < 0.001).
• No significant changes in CTX or TP1NP in the non-remission group compared to pre-operation levels.
• Pearson correlation revealed a significant association between β-CTX and SAGIT score (r=0.356, p=0.049).
• Multivariate regression identified β-CTX as an independent risk factor for SAGIT score (p=0.001).

Conclusions:

• Bone metabolism indicators are closely associated with acromegaly status and treatment response.
• The β-CTX value demonstrates potential as an effective biomarker for assessing acromegaly.
• Further research can elucidate the role of β-CTX in acromegaly management and prognosis.